Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 20/20 | 0.78 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.55 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.55 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.55 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20568227 | 0.93 | PDE5A (0.87) | PDE5APDE3BPDE3A | |
| SCHEMBL20568229 | 0.93 | PDE5A (0.87) | PDE5APDE3BPDE3A | |
| SCHEMBL22066540 | 0.91 | PDE5A (0.82) | PDE5APDE3BPDE3A | |
| SCHEMBL20567814 | 0.90 | PDE5A (0.94) | PDE5A | |
| SCHEMBL22028314 | 0.90 | PDE5A (0.94) | PDE5A | |
| SCHEMBL20567813 | 0.90 | PDE5A (0.94) | PDE5A | |
| SCHEMBL31651388 | 0.90 | PDE5A (0.94) | PDE5A | |
| SCHEMBL22066556 | 0.90 | PDE5A (0.71) | PDE5AHDAC1HDAC2HDAC6PDE3B | |
| SCHEMBL22028295 | 0.89 | PDE5A (0.84) | PDE5AHDAC1HDAC2HDAC6PDE3B | |
| SCHEMBL22028296 | 0.89 | PDE5A (0.84) | PDE5AHDAC1HDAC2HDAC6PDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220073529-A1 | DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | TOPADUR PHARMA AG (CH) | 2022-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220073529-A1 | DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | PDE5A, PDE1A, PDE2A | PDE5A 1/4885HDAC1 919/4885HDAC2 1160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.